Recently, a research team led by Profs. LIU Qingsong and LIU Jing from the Institute of Health & Medical Technology of the Hefei Institutes of Physical Science (HFIPS) discovered a potent and selective PI3Kδ inhibitor IHMT-PI3Kδ-372, which exhibited anti- Chronic Obstructive Pulmonary Disease (COPD) efficacy in vivo.
COPD is a chronic progressive respiratory disease characterized by airflow limitation and associated with abnormal inflammatory response of the lung. In recently years, it is becoming a major health problem and the third cause of death worldwide. Although oral administration of PI3Kδ inhibitor is reported to exhibit adverse effects as an anti-cancer drug in the clinic, inhaled drug delivery for respiratory disease may result in a potential reduction or avoidance of systemic side effects by delivering drugs directly to the site of action.
In this study, the researchers adopted a fragment hybridization strategy and discovered a novel PI3Kδ inhibitor IHMT-PI3Kδ-372 through medicinal chemistry exploration.
The compound showed high potency against PI3Kδ, and meanwhile exhibited high selectivity over other class I PI3Ks as well as a low risk of hERG-mediated cardiac toxicity. Notably, it displayed favorable pharmacokinetic properties for inhaled delivery and improved lung function in a rodent model of pulmonary inflammation.
These results suggest that IHMT-PI3Kδ-372 might be a new potential therapeutic candidate for COPD.
In vivo efficacy evaluation of IHMT-PI3Kδ-372 in a lung inflammation rodent model (Image by LI Feng)
86-10-68597521 (day)
86-10-68597289 (night)
86-10-68511095 (day)
86-10-68512458 (night)
cas_en@cas.cn
52 Sanlihe Rd., Xicheng District,
Beijing, China (100864)
Copyright © 2002 - Chinese Academy of Sciences
